{
    "title": "The ASNR-MICCAI Brain Tumor Segmentation (BraTS) Challenge 2023: Intracranial Meningioma. (arXiv:2305.07642v1 [cs.CV])",
    "abstract": "Meningiomas are the most common primary intracranial tumor in adults and can be associated with significant morbidity and mortality. Radiologists, neurosurgeons, neuro-oncologists, and radiation oncologists rely on multiparametric MRI (mpMRI) for diagnosis, treatment planning, and longitudinal treatment monitoring; yet automated, objective, and quantitative tools for non-invasive assessment of meningiomas on mpMRI are lacking. The BraTS meningioma 2023 challenge will provide a community standard and benchmark for state-of-the-art automated intracranial meningioma segmentation models based on the largest expert annotated multilabel meningioma mpMRI dataset to date. Challenge competitors will develop automated segmentation models to predict three distinct meningioma sub-regions on MRI including enhancing tumor, non-enhancing tumor core, and surrounding nonenhancing T2/FLAIR hyperintensity. Models will be evaluated on separate validation and held-out test datasets using standardized metri",
    "link": "http://arxiv.org/abs/2305.07642",
    "context": "Title: The ASNR-MICCAI Brain Tumor Segmentation (BraTS) Challenge 2023: Intracranial Meningioma. (arXiv:2305.07642v1 [cs.CV])\nAbstract: Meningiomas are the most common primary intracranial tumor in adults and can be associated with significant morbidity and mortality. Radiologists, neurosurgeons, neuro-oncologists, and radiation oncologists rely on multiparametric MRI (mpMRI) for diagnosis, treatment planning, and longitudinal treatment monitoring; yet automated, objective, and quantitative tools for non-invasive assessment of meningiomas on mpMRI are lacking. The BraTS meningioma 2023 challenge will provide a community standard and benchmark for state-of-the-art automated intracranial meningioma segmentation models based on the largest expert annotated multilabel meningioma mpMRI dataset to date. Challenge competitors will develop automated segmentation models to predict three distinct meningioma sub-regions on MRI including enhancing tumor, non-enhancing tumor core, and surrounding nonenhancing T2/FLAIR hyperintensity. Models will be evaluated on separate validation and held-out test datasets using standardized metri",
    "path": "papers/23/05/2305.07642.json",
    "total_tokens": 1047,
    "translated_title": "ASNR-MICCAI脑肿瘤分割挑战2023：颅内脑膜瘤",
    "translated_abstract": "脑膜瘤是成人颅内最常见的原发性肿瘤，可能与重大的发病率和死亡率有关。放射科医生、神经外科医生、神经肿瘤学家和放射肿瘤科医生依靠多参数MRI（mpMRI）进行诊断、治疗规划和长期治疗监测；然而，缺乏自动化、客观化和定量化的工具来对mpMRI中的脑膜瘤进行非侵入性评估。BraTS脑膜瘤2023挑战将提供一个社区标准和基于迄今为止最大的专家注释的多标签脑膜瘤mpMRI数据集的最先进自动化颅内脑膜瘤分割模型的基准。挑战参赛者将开发自动化分割模型，预测MRI上的三个不同的脑膜瘤亚区域，包括增强肿瘤、非增强肿瘤核心和周围无增强T2/FLAIR高信号区。模型将使用标准化指标在单独的验证和保留测试数据集上进行评估。",
    "tldr": "ASNR-MICCAI脑肿瘤分割挑战2023将提供一个适用于自动诊断颅内脑膜瘤的最先进自动化颅内脑膜瘤分割模型的基准。",
    "en_tdlr": "The ASNR-MICCAI Brain Tumor Segmentation (BraTS) Challenge 2023 will provide a benchmark for state-of-the-art automated intracranial meningioma segmentation models, aiming to develop automated segmentation models to predict three distinct meningioma sub-regions on MRI, enhancing tumor, non-enhancing tumor core, and surrounding nonenhancing T2/FLAIR hyperintensity."
}